About the OncoPed
Select Assay

More than one year ago, leaders from PierianDx and leading children’s hospitals discussed how to fill a glaring gap in pediatric oncology; there was no clinically-focused pediatric somatic cancer assay on the market. Additionally, many children’s hospitals across the country didn’t have the volume needed to warrant the validation of such specific genomic testing for children.

The result of this feedback was the creation of OncoPed Select, malignancy and research panels specifically tailored to address childhood cancers. The OncoPed assays are the right balance between assay breadth, depth and price.

Contact us today about the OncoPed Select Assay – the right fit for the right cause.

Contact Us

OncoPed Select Features

  • Validated by leading children’s hospitals and PierianDx, the forerunner in clinical genomic analysis, interpretation and reporting

  • Created to achieve the right balance between gene breadth, depth and affordability

  • Between 14 and 21 days turnaround time (TAT)

  • Unlike the traditional “send out” model, the partner has the option to retain all data, brand the test as their own, and review and sign out cases

Frequently Asked Questions

Get Started

Ready to get started? Contact PierianDx today!

CONTACT US

Get Started

Ready to get started? Contact PierianDx today!

CONTACT USBrochure

Upcoming Events

OncoPed Showcase Luncheon
Join us October 7, 2016 at 12:15pm at the Waikiki Beach Marriott Resort & Spa for a question and answer lunch showcasing the first clinically available pediatric somatic assay presented in association with Seattle Children’s Hospital.

RSVP TODAY

Get Started

Ready to get started? Contact PierianDx today!

CONTACT US Brochure